Press Releases

01/02/2024

Tempus Announces Participation in National Cancer Institute’s ComboMATCH Trials

Tempus, a leader in artificial intelligence and precision medicine, today announced its participation in the National Cancer Institute’s (NCI) ComboMATCH group of precision medicine trials. The ComboMATCH trials aim to pair patients with a therapy that has the potential to manage their tumor and help assist physicians in devisi...

10/20/2023

Oncology

Tempus Announces Five Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced five abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2023, which convenes in Madrid, Spain, from October 20-24, 2023. "We are excited to share our latest research at ESMO this year, as we continue to make our precision medici...

08/15/2023

Oncology

FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test. The test uses a machine learning model to analyze sequence data produced b...

07/12/2023

Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study

Study aims to create the most robust, multi-omic dataset for patients with NSCLC Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset...

06/21/2023

Tempus Launches Standalone RNA Sequencing Test, xR

Tempus, a leader in artificial intelligence and precision medicine, today introduces its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. Tempus has always understood the importa...

06/02/2023

Oncology

Tempus Exhibits 20 Abstracts at the 2023 American Society of Clinical Oncology Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced the company will exhibit 20 abstracts at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from June 2-6, in Chicago, Illinois. This year, Tempus is presenting its latest research via two oral presentations, one poster discussion session, and...

06/01/2023

Tempus Announces Broad Launch of Tempus One

AI-enabled clinical assistant provides access to patient insights directly at your fingertips Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the upcoming broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at...

04/14/2023

Tempus Announces Seven Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced seven abstracts were accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 14-19, in Orlando, Florida. Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and a...

02/28/2023

Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and deve...

01/05/2023

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is cur...

NEWS

Media Coverage

Additional Partnerships